Stock Events

Stock Events

Rezolute 

$3.05
0
+$0.01+0.33% Today

Statistics

Day High
3.14
Day Low
3.05
52W High
-
52W Low
-
Volume
10,031
Avg. Volume
-
Mkt Cap
291.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-0.24
-0.22
-0.2
-0.18
Expected EPS
-0.1808
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-148.82MNet Income

Analyst Ratings

$7.60Average Price Target
The highest estimate is 17.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RZLT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. operates in the biopharmaceutical field focusing on RNAi therapeutics for the treatment of rare genetic diseases, competing in the same rare disease space as Rezolute.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, directly competing with Rezolute's approach to treating rare diseases through innovative therapies.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics, Inc. is involved in the development of therapies for metabolic and endocrine disorders, directly competing with Rezolute's metabolic disease focus.
Seres Therapeutics
MCRB
Mkt Cap140.95M
Seres Therapeutics, Inc. is engaged in microbiome therapeutics for metabolic diseases, which places it in direct competition with Rezolute's metabolic disease treatments.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics, Inc. focuses on the discovery and commercialization of novel medicines to treat rare disorders, directly competing with Rezolute in the rare disease market.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, competing in the rare disease space alongside Rezolute.

About

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Show more...
CEO
ISIN
US76200L3096

Listings

F
DE
6HV1.F
BOATS
BOATS
RZLT.BOATS
XNAS
US
RZLT

0 Comments

Share your thoughts

FAQ

What is Rezolute stock price today?▼
The current price of RZLT.BOATS is $3.05 USD — it has increased by +0.33% in the past 24 hours. Watch Rezolute stock price performance more closely on the chart.
What is Rezolute stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rezolute stocks are traded under the ticker RZLT.BOATS.
What is Rezolute market cap?▼
Today Rezolute has the market capitalization of 291.88M
When is the next Rezolute earnings date?▼
Rezolute is going to release the next earnings report on May 13, 2026.
What were Rezolute earnings last quarter?▼
RZLT.BOATS earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.19 USD resulting in a -17.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rezolute revenue for the last year?▼
Rezolute revenue for the last year amounts to 0 USD.
What is Rezolute net income for the last year?▼
RZLT.BOATS net income for the last year is -148.82M USD.
When did Rezolute complete a stock split?▼
Rezolute has not had any recent stock splits.